ArticleFrontiers in neurology2025
Tubridge flow-diverting stent for treatment of unruptured intracranial complex aneurysms.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of flow diverters for the treatment of intracranial aneurysms: a systematic review and meta-analysis.Frontiers in surgery · 2026Pooled it
- Preliminary experience of Tubridge Plus flow diverter in the treatment of intracranial aneurysms.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the efficacy and safety of the Tubridge flow diverter (TFD) in treating unruptured intracranial complex aneurysms. Methods: A retrospectively was performed on consecutive patients with unruptured intracranial complex aneurysms treated with TFD at our institution between October 2019 and December 2022. Clinical data, including demographic characteristics, angiographic findings, and follow-up outcomes, were collected to assess postoperative and follow-up aneurysm occlusion rates. Complications and clinical outcomes were evaluated, with favorable outcomes defined as a modified Rankin Scale (mRS) score of 0-2. Results: A total of 72 patients harboring 75 aneurysms were included, with 47 aneurysms treated with TFD alone and 28 undergoing combined TFD and coiling. Fifty-six aneurysms in 53 patients underwent at least one digital subtraction angiography (DSA) examination. The median follow-up duration at the final visit was 156.00 days, yielding a successful aneurysm occlusion rate of 78.57% (44/56) and a median time to occlusion of 139.00 days. The complete occlusion rate was significantly higher in non-saccular aneurysms (92.86%, 13/14) than in saccular aneurysms (64.29%, 27/42). Severe stenosis (>50%) occurred in 3 of 55 stents (5.45%). Among 67 patients (5 lost to follow-up), 4 ischemic and 8 hemorrhagic complications were recorded, with 97.01% of patients achieving an mRS score of 0-1. Conclusion: Small-to-medium-sized aneurysms (maximum diameter <10 mm) can be effectively managed with TFD alone. TFD demonstrates minimal impact on branch vessels, and patients with mild in-stent stenosis may be monitored without intervention. The TFD is safe and effective for treating various types of unruptured intracranial complex aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.